PMID-11146367 – AOD9604 Metabolic Studies Lipolytic Domain
Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;54(2):65-68.
Quick Reference
| Property | Value |
|---|---|
| PMID | 11146367 |
| DOI | 10.1159/000053183 |
| Year | 2000 |
| Journal | Hormone Research |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Obese Zucker rats (multiple cohorts) |
| Peptide(s) Studied | AOD-9604 |
Key Findings
- AOD9604 administered orally reduced body weight gain by more than 50% in obese Zucker rats compared to controls
- Unlike full-length human growth hormone, AOD9604 did not impair insulin sensitivity or glucose tolerance
- Oral bioavailability was demonstrated, establishing AOD9604 as a viable oral peptide therapeutic candidate
- The lipolytic domain (residues 177-191 of hGH) retained fat-metabolizing activity independent of the growth-promoting actions of full GH
- AOD9604 did not stimulate IGF-1 production, confirming its mechanism is distinct from the GH receptor pathway
Study Design
Multiple cohorts of obese Zucker rats were treated with oral AOD9604 over varying durations. Body weight, fat mass, insulin sensitivity, and glucose tolerance were measured. Comparisons were made against vehicle controls and in some experiments against full-length hGH to differentiate metabolic effects.
Limitations
- Zucker rat obesity model is genetic (leptin receptor deficient) and may not fully translate to human diet-induced obesity
- Small sample sizes typical of early exploratory studies
- No pharmacokinetic profiling of oral absorption was reported in detail
- Single animal model used
Clinical Relevance
This foundational study established the key pharmacological profile of AOD9604: lipolytic activity without the diabetogenic or growth-promoting effects of full GH. The demonstration of oral bioavailability was particularly significant, as most peptides require injection. This work laid the groundwork for clinical development of AOD9604 as an anti-obesity agent.
Related
#research #animal-in-vivo #AOD-9604 #evidence-level-V